In patients with HER2-negative and low hormone receptors (HRs) expression metastatic BC, Montagna, and colleagues conducted a phase II clinical trial combining MCT (CTX + CPB) with antiangiogenic bevacizumab with erlotinib. Here, ERBB2 is linked to breast cancer.